Tomas Luther1, Sara Bülow-Anderberg1, Anders Larsson2, Sten Rubertsson1, Miklos Lipcsey1,3, Robert Frithiof1, Michael Hultström1,4. 1. Department of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden. 2. Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden. 3. Hedenstierna laboratory, CIRRUS, Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. 4. Department of Medical Cell Biology, Integrative Physiology, Uppsala University, Uppsala, Sweden.
Abstract
BACKGROUND: Acute kidney injury (AKI) is a syndrome of reduced glomerular filtration rate and/or reduced urine flow associated with mortality in corona virus disease 2019 (COVID-19). AKI is often associated with renal tissue damage, which may lead to chronic kidney disease. Biomarkers of tissue damage may identify patients of particular risk. METHODS: In a prospective observational study of 57 patients admitted to intensive care, AKI incidence and characteristics was evaluated according to KDIGO criteria and related to days after admission. Urinary albumin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule 1 (KIM-1) and Plasma Tissue Inhibitor of MetalloProteinase 2 (TIMP-2) were analysed in 52 patients at admission. The majority (n = 51, 89%) of patients developed AKI, and 27 (47%) patients had predominantly oliguric AKI where oliguria was more severe than plasma Creatinine increase. Severe oliguria within first 2 days after admission was common (n = 37, 65%), whereas stage 2 and 3 AKI due to Creatinine occurred later than day 2 in 67% (12/18) of cases. Renal replacement therapy was started in 9 (16%) patients, and 30-day mortality was 28%. Urinary biomarkers were increased in a majority of patients, but did not robustly predict KDIGO stage. Most patients had microalbuminuria, and severe albuminuria (albumin Creatinine ratio > 30 mg/mmol) was found in n = 9 (17%) patients. CONCLUSIONS: A majority of patients with COVID-19 admitted to the ICU develop AKI. The functional deficit is often low urinary volume, and initial levels of biomarkers are generally increased without clear relation to final AKI stage.
BACKGROUND: Acute kidney injury (AKI) is a syndrome of reduced glomerular filtration rate and/or reduced urine flow associated with mortality in corona virus disease 2019 (COVID-19). AKI is often associated with renal tissue damage, which may lead to chronic kidney disease. Biomarkers of tissue damage may identify patients of particular risk. METHODS: In a prospective observational study of 57 patients admitted to intensive care, AKI incidence and characteristics was evaluated according to KDIGO criteria and related to days after admission. Urinary albumin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule 1 (KIM-1) and Plasma Tissue Inhibitor of MetalloProteinase 2 (TIMP-2) were analysed in 52 patients at admission. The majority (n = 51, 89%) of patients developed AKI, and 27 (47%) patients had predominantly oliguric AKI where oliguria was more severe than plasma Creatinine increase. Severe oliguria within first 2 days after admission was common (n = 37, 65%), whereas stage 2 and 3 AKI due to Creatinine occurred later than day 2 in 67% (12/18) of cases. Renal replacement therapy was started in 9 (16%) patients, and 30-day mortality was 28%. Urinary biomarkers were increased in a majority of patients, but did not robustly predict KDIGO stage. Most patients had microalbuminuria, and severe albuminuria (albumin Creatinine ratio > 30 mg/mmol) was found in n = 9 (17%) patients. CONCLUSIONS: A majority of patients with COVID-19 admitted to the ICU develop AKI. The functional deficit is often low urinary volume, and initial levels of biomarkers are generally increased without clear relation to final AKI stage.
Authors: John A Kellum; Florentina E Sileanu; Raghavan Murugan; Nicole Lucko; Andrew D Shaw; Gilles Clermont Journal: J Am Soc Nephrol Date: 2015-01-07 Impact factor: 10.121
Authors: Molly Fisher; Joel Neugarten; Eran Bellin; Milagros Yunes; Lindsay Stahl; Tanya S Johns; Matthew K Abramowitz; Rebecca Levy; Neelja Kumar; Michele H Mokrzycki; Maria Coco; Mary Dominguez; Kalyan Prudhvi; Ladan Golestaneh Journal: J Am Soc Nephrol Date: 2020-07-15 Impact factor: 10.121
Authors: Sara Nisula; Kirsi-Maija Kaukonen; Suvi T Vaara; Anna-Maija Korhonen; Meri Poukkanen; Sari Karlsson; Mikko Haapio; Outi Inkinen; Ilkka Parviainen; Raili Suojaranta-Ylinen; Jouko J Laurila; Jyrki Tenhunen; Matti Reinikainen; Tero Ala-Kokko; Esko Ruokonen; Anne Kuitunen; Ville Pettilä Journal: Intensive Care Med Date: 2013-01-05 Impact factor: 17.440
Authors: Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Sanna Törnblom; Sara Nisula; Liisa Petäjä; Suvi T Vaara; Mikko Haapio; Eero Pesonen; Ville Pettilä Journal: Ann Intensive Care Date: 2020-04-28 Impact factor: 6.925
Authors: Alexandra C Walls; Young-Jun Park; M Alejandra Tortorici; Abigail Wall; Andrew T McGuire; David Veesler Journal: Cell Date: 2020-03-09 Impact factor: 41.582
Authors: Tomas Luther; Sara Bülow-Anderberg; Anders Larsson; Sten Rubertsson; Miklos Lipcsey; Robert Frithiof; Michael Hultström Journal: Acta Anaesthesiol Scand Date: 2020-11-28 Impact factor: 2.274
Authors: Bo Nilsson; Barbro Persson; Oskar Eriksson; Karin Fromell; Michael Hultström; Robert Frithiof; Miklos Lipcsey; Markus Huber-Lang; Kristina N Ekdahl Journal: Front Immunol Date: 2022-03-08 Impact factor: 7.561
Authors: Jacob Rosén; Maria Noreland; Karl Stattin; Miklós Lipcsey; Robert Frithiof; Andrei Malinovschi; Michael Hultström Journal: PLoS One Date: 2021-12-14 Impact factor: 3.240
Authors: Tomas Luther; Sara Bülow-Anderberg; Anders Larsson; Sten Rubertsson; Miklos Lipcsey; Robert Frithiof; Michael Hultström Journal: Acta Anaesthesiol Scand Date: 2020-11-28 Impact factor: 2.274